Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Acute Myelogenous Leukemia (899
)
Acute Lymphocytic Leukemia (388
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Acute Myelogenous Leukemia (899
)
Acute Lymphocytic Leukemia (388
)
Chronic Lymphocytic Leukemia (292
)
Chronic Myeloid Leukemia (255
)
B Acute Lymphoblastic Leukemia (163
)
T Acute Lymphoblastic Leukemia (38
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Chronic Eosinophilic Leukemia (4
)
Juvenile Myelomonocytic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(1940)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
NCCN - 2 weeks (New A2)
olutasidenib
Sensitive
:
A1
NCCN - 2wk
olutasidenib
Sensitive: A1 - Approval
NCCN - 2 weeks
olutasidenib
Sensitive
:
A1
NCCN - 2 weeks - (New A2)
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
C1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
C1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
C1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
C1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
CD33 positive
Acute Myelogenous Leukemia
CD33 positive
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
C1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
omacetaxine mepesuccinate
Sensitive: A1 - Approval
omacetaxine mepesuccinate
Sensitive
:
A1
omacetaxine mepesuccinate
Sensitive: A1 - Approval
omacetaxine mepesuccinate
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
CD20 expression
Chronic Lymphocytic Leukemia
CD20 expression
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
blinatumomab
Sensitive: A1 - Approval
blinatumomab
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login